Photo by drown_in_city from unsplash
Little is known about the risk of angioedema with low-dose alteplase administration in the treatment of thrombotically occluded central vascular access devices (CVADs). To identify potential cases, the US Food… Click to show full abstract
Little is known about the risk of angioedema with low-dose alteplase administration in the treatment of thrombotically occluded central vascular access devices (CVADs). To identify potential cases, the US Food and Drug Administration Adverse Event Reporting System database was searched. Between March 15, 2001, and August 15, 2018, there were 568 low-dose alteplase reports. Of these, 11 appear to be related to complications associated with a device or device occlusion that resulted in an angioedema-like reaction. This suggests that angioedema is a potential complication of alteplase when used for declotting CVADs—a complication that nurses should know how to recognize and treat.
Journal Title: Journal of Infusion Nursing
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!